Inhibitory effects of TRK-530 on rat adjuvant arthritis

被引：21

作者：

Tanahashi, M ^{[1
]}

Funaba, Y ^{[1
]}

Itoh, M ^{[1
]}

Kawabe, N ^{[1
]}

Nakadate-Matsushita, T ^{[1
]}

机构：

[1] Toray Ind Inc, Basic Res Labs, Kanagawa 248, Japan

来源：

PHARMACOLOGY | 1998年 / 56卷 / 05期

关键词：

TRK-530; bisphosphonate; adjuvant arthritis; interleukin-1;

D O I：

10.1159/000028204

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

TRK-530 is a novel bisphosphonate derivative. We examined the anti-inflammatory effects of TRK-530 on adjuvant arthritis (AA) rats. When TRK-530 at a dose of 2.5 mg/kg was administered for 2 weeks to AA rats, it inhibited destructive changes in arthritic joints such as paw edema, bone loss and joint degeneration. TRK-530 also inhibited splenomegaly and suppressed the increase in serum sialic acid which is measured as a systemic parameter of inflammation. To clarify the inhibitory mechanism of TRK-530, interleukin-1 (IL-1)-like activities of resident peritoneal macrophages in AA rats given TRK-530 were compared with those of control rats. We found that TRK-530 inhibited IL-1-like activity induced by bacterial lipopolysaccharide 6 weeks after administration when the IL-1-like activities of control rats were still at high levels, These findings suggest that TRK-530 exerts anti-inflammatory activities in AA rats.

引用

页码：242 / 251

页数：10

共 27 条

[1] THE ACUTE-PHASE RESPONSE AFTER BISPHOSPHONATE ADMINISTRATION [J].